Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Maviret Shrivels, but AbbVie Japan in “Growth Mode” with Oncology, Immunology Drivers: Chief
AbbVie saw a dip in its Japan revenue in 2019 in a pullback from the previous year’s spike on the hepatitis C drug Maviret (glecaprevir + pibrentasvir), but its topline still crossed the 100 billion yen mark for the second…
To read the full story
Related Article
- AbbVie Japan Looks to Double Sales by 2029 with Rinvoq and Skyrizi as Engines
June 12, 2025
- AbbVie Japan Eyes Sales of 200 Billion Yen in 5 Years, Rinvoq and Skyrizi as Drivers
May 29, 2024
- AbbVie Aims to Double Japan Sales to 200 Billion Yen by 2030: Local Chief
May 31, 2023
- AbbVie’s Japan Sales Sag 13% in 2021 as Off-Year Price Cuts, Synagis Return Weigh
May 19, 2022
- AbbVie Looks to Continue Double-Digit Annual Growth in New 5-Year Biz Plan
May 21, 2021
- AbbVie Japan Set to Join Oncology Fray with CLL Drug, Accelerating FIH Trial Entry
October 9, 2019
- AbbVie’s Japan Sales in 2018 Double on Maviret Boon
May 23, 2019
BUSINESS
- Leqembi Iqlik Now under FDA Review for Initiation Phase
January 26, 2026
- Regeneron Japan Launches Scholarship for STEM-Oriented High School Students
January 26, 2026
- JCR Expects Strong Returns from Recently In-Licensed DMD Drug: CEO
January 26, 2026
- Solasia to Grant MAAB Rights to Antiemetic Drug in China
January 26, 2026
- Toho Seeks Additional Disclosure from 3D over Proposed Share Purchases
January 26, 2026
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…